The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Newcastle upon Tyne Hospitals NHS Foundation EHA 2026 | Real-world data support bispecific antibodies in large B-cell lymphoma
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, reviews UK real-world data on glofitamab and epcoritamab in large B-cell lymphoma (DLBCL), highlighting durable responses, manageable toxicity, and practical guidance for safely delivering bispecific antibodies in community practice. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
